The largest database of trusted experimental protocols

4 protocols using granzyme b pe texas red

1

Anti-PD-1 and Anti-CTLA4 Antibody Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Therapeutic anti-PD-1 (clone RMP1-14) and anti-CTLA4 (9H10) monoclonal antibodies were produced by BioXcell. Antibodies used for flow cytometry were purchased from the following sources (dilutions are indicated in parentheses): eBioscience (CD45.2 Alexa Fluor 700, cat: 56-0454 (1:200), CD3 PE-Cy7, cat: 25-0031 (1:200), CD4 ef450, cat: 48-0041 (1:200), CD8 PerCP-efluor710, cat: 46-0083 (1:200), CD11b APC-efluor 780, cat: 47-0112 (1:600), ICOS PE, cat: 12-5985 (1:200), PD-L1 PE Cy7, cat: 25-5982-82 (1:200), FoxP3 Alexa Fluor 700, cat: 56-5773 (1:100), FoxP3 APC, cat: 17-5773 (1:200), PD-1 PE-Cy7, cat: 25-9985 (1:200)), Invitrogen (Granzyme B PE-Texas Red, cat: GRB17 (1:125)) and BD Pharmingen (Ki67-Alexa Fluor 488, cat: 561165 (1:50)).
+ Open protocol
+ Expand
2

Antibody-mediated Immune Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Therapeutic anti-CTLA-4 (clone 9H10) antibody and isotype control antibody was purchased from BioXcell (cat: BE0131 and BE0087). Antibodies used for flow cytometry were purchased from the following sources (dilutions are indicated in parentheses): eBioscience (CD45.2 Alexa Fluor 700, cat: 56-0454 (1:200), CD3 PE-Cy7, cat: 25-0031 (1:200), CD4 ef450, cat: 48-0041 (1:200), CD4 APC-efluor780, cat: 47-0041 (1:400), CD8 PerCP-efluor710, cat: 46-0083 (1:200), CD11b APC-efluor 780, cat: 47-0112 (1:600), ICOS PE, cat: 12-5985 (1:200), ICOSL PE, cat: 12-5985 (1:200), CTLA-4 PE, cat: 12-1522 (1:200), NK1.1 PE, cat: 12-5941 (1:200), IFNγ PE, cat: 12-7311 (1:200), FoxP3 Alexa Fluor 700, cat: 56-5773 (1:100), FoxP3 APC, cat: 17-5773 (1:200), GATA-3 PE, cat: 12-9966 (1:100), RORγT PerCP-efluor710, cat: 46-6981 (1:100), Tbet PE-Cy7, cat: 25-5825 (1:100), EOMES efluor 450, cat: 48-4875 (1:100), PD-1 PE-Cy7, cat: 25-9985, (1:200)), Biolegend (CD3 BV570, cat: 100225 (1:100), CD11b BV570, cat: 101233 (1:50), Bcl-6 Alexa 594, cat: 648308 (1:50)), Invitrogen (Granzyme B PE-Texas Red, cat: GRB17 (1:125), Granzyme B APC, cat: GRB05 (1:125)) and BD Pharmingen (Ki-67-Alexa Fluor 488, cat: 561165 (1:50), CXCR5-biotin, cat: 551960 (1:100)).
+ Open protocol
+ Expand
3

Immunotherapeutic Response Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercial sources for reagents were as follows: CpG oligodeoxynucleotide ODN2216 (Invitrogen); We used the following antibodies. Therapeutic anti-CTLA4 (clone 9H10 and 9D9), anti-PD1 (clone RMP1-14), anti-PD-L1 (clone 10F.9G2) were purchased from BioXcell; Antibodies used for flow cytometry were purchased from eBioscience (CD45.2 Alexa Fluor 700, CD3 PE-Cy7, CD4 APC-efluor780, CD8 PerCP-efluor710, FOXP3 Alexa Fluor 700, MHC Class I APC, CD40 APC, CD80 APC, CD86 APC), Invitrogen (CD4 QDot 605, Granzyme B PE-Texas Red, Granzyme B APC), BD Pharmingen (Ki-67-Alexa Fluor 488).
+ Open protocol
+ Expand
4

Multiparameter Flow Cytometric Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercial sources for reagents were as follows: Antibodies used for flow cytometry were purchased from eBioscience (Live/Dead eFluor 506, CD45.2 Alexa Fluor 700, CD3 PE-Cy7, CD4 Pacific blue-eFluor 450, CD8 PerCP-efluor710, CD11b APC-eFluor 780, MHC Class I APC, CD40 APC, CD80 APC, CD86 APC), Invitrogen (granzyme B PE-Texas Red), and BD Pharmingen (CD11c-PE-Cy7). Murine anti-GM-CSF antibody was purchased from Thermo Fisher. DNAse I and Liberase TL were purchased from Roche. Recombinant murine GM-CSF protein was purchased from GenScript. Therapeutic anti-CTLA4 (clone 9H10 and 9D9) and anti-PD-L1 (clone 10F.9G2) were purchased from BioXcell.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!